Navidea Biopharmaceuticals, Inc. financial data

Symbol
NAVB on OTC
Industry
In Vitro & In Vivo Diagnostic Substances
Location
4995 Bradenton Avenue, Suite 240, Dublin, OH
State of incorporation
DE
Fiscal year end
December 31
Former names
NEOPROBE CORP (to 12/30/2011)
Latest financial report
10-Q - Q3 2023 - Nov 14, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 44.8 % -23.1%
Quick Ratio 5.1 % +24.1%
Debt-to-equity -186 % +24%
Operating Margin -21.4K % -843%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 100M shares +209%
Common Stock, Shares, Outstanding 100M shares +211%
Entity Public Float 14.3M USD -60.3%
Common Stock, Value, Issued 287K USD +29.7%
Weighted Average Number of Shares Outstanding, Basic 99.4M shares +223%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD -100%
Cost of Revenue 1.94K USD
Research and Development Expense 5.09M USD -6.58%
Operating Income (Loss) -10.2M USD +29.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -2.26M USD +60.5%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -5.71M USD -134%
Earnings Per Share, Basic -0.06 USD/shares +89.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.86M USD -16%
Inventory, Net 461K USD +138%
Assets, Current 4.5M USD -11.7%
Property, Plant and Equipment, Net 109K USD -27%
Operating Lease, Right-of-Use Asset 10.6K USD -71%
Other Assets, Noncurrent 11.8K USD -62.9%
Assets 5.7M USD -8.94%
Accounts Payable, Current 2.01M USD -17.3%
Employee-related Liabilities, Current 788K USD -34%
Liabilities, Current 7.98M USD -5.39%
Contract with Customer, Liability, Noncurrent 700K USD 0%
Operating Lease, Liability, Noncurrent 269 USD -84.1%
Liabilities 8.68M USD -20.6%
Retained Earnings (Accumulated Deficit) -386M USD -0.36%
Stockholders' Equity Attributable to Parent -3.27M USD +34%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -2.98M USD +36.1%
Liabilities and Equity 5.7M USD -8.94%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.72M USD +32.6%
Net Cash Provided by (Used in) Financing Activities -201K USD +40.9%
Net Cash Provided by (Used in) Investing Activities -39.4K USD +66.7%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 100M shares +211%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.96M USD +34.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 118K USD +3074%
Deferred Tax Assets, Valuation Allowance 51.2M USD +5.62%
Deferred Tax Assets, Gross 51.2M USD +5.62%
Operating Lease, Liability 10.7K USD -63.2%
Payments to Acquire Property, Plant, and Equipment 36.1K USD -46.3%
Lessee, Operating Lease, Liability, to be Paid 10.8K USD -64.6%
Property, Plant and Equipment, Gross 733K USD -12.3%
Operating Lease, Liability, Current 10.4K USD -61.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.36K USD -93.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.36K USD -93.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 102 USD -93%
Deferred Tax Assets, Operating Loss Carryforwards 39.2M USD +6.54%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 9.44K USD -89.9%
Additional Paid in Capital 382M USD +0.79%
Depreciation, Depletion and Amortization 27.6K USD +20.4%
Share-based Payment Arrangement, Expense 136K USD -74.5%